Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...

Full description

Bibliographic Details
Main Authors: Véronique Hofman, Sandra Lassalle, Coraline Bence, Elodie Long-Mira, Sacha Nahon-Estève, Simon Heeke, Virginie Lespinet-Fabre, Catherine Butori, Marius Ilié, Paul Hofman
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Cancers
Subjects:
predictive biomarkers
lung cancer
immunohistochemistry
immunocytochemistry
immune-oncology
Online Access:http://www.mdpi.com/2072-6694/10/3/70

Similar Items

Similar Items